332 related articles for article (PubMed ID: 22952447)
1. Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees.
Morin TJ; Broering TJ; Leav BA; Blair BM; Rowley KJ; Boucher EN; Wang Y; Cheslock PS; Knauber M; Olsen DB; Ludmerer SW; Szabo G; Finberg RW; Purcell RH; Lanford RE; Ambrosino DM; Molrine DC; Babcock GJ
PLoS Pathog; 2012; 8(8):e1002895. PubMed ID: 22952447
[TBL] [Abstract][Full Text] [Related]
2. Identification and characterization of broadly neutralizing human monoclonal antibodies directed against the E2 envelope glycoprotein of hepatitis C virus.
Broering TJ; Garrity KA; Boatright NK; Sloan SE; Sandor F; Thomas WD; Szabo G; Finberg RW; Ambrosino DM; Babcock GJ
J Virol; 2009 Dec; 83(23):12473-82. PubMed ID: 19759151
[TBL] [Abstract][Full Text] [Related]
3. High-throughput sequencing analysis of post-liver transplantation HCV E2 glycoprotein evolution in the presence and absence of neutralizing monoclonal antibody.
Babcock GJ; Iyer S; Smith HL; Wang Y; Rowley K; Ambrosino DM; Zamore PD; Pierce BG; Molrine DC; Weng Z
PLoS One; 2014; 9(6):e100325. PubMed ID: 24956119
[TBL] [Abstract][Full Text] [Related]
4. A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo.
Desombere I; Mesalam AA; Urbanowicz RA; Van Houtte F; Verhoye L; Keck ZY; Farhoudi A; Vercauteren K; Weening KE; Baumert TF; Patel AH; Foung SKH; Ball J; Leroux-Roels G; Meuleman P
Antiviral Res; 2017 Dec; 148():53-64. PubMed ID: 29074219
[TBL] [Abstract][Full Text] [Related]
5. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.
Law JLM; Logan M; Wong J; Kundu J; Hockman D; Landi A; Chen C; Crawford K; Wininger M; Johnson J; Mesa Prince C; Dudek E; Mehta N; Tyrrell DL; Houghton M
J Virol; 2018 Jun; 92(11):. PubMed ID: 29540595
[TBL] [Abstract][Full Text] [Related]
6. Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity.
Keck ZY; Li SH; Xia J; von Hahn T; Balfe P; McKeating JA; Witteveldt J; Patel AH; Alter H; Rice CM; Foung SK
J Virol; 2009 Jun; 83(12):6149-60. PubMed ID: 19321602
[TBL] [Abstract][Full Text] [Related]
7. Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV.
Forns X; Payette PJ; Ma X; Satterfield W; Eder G; Mushahwar IK; Govindarajan S; Davis HL; Emerson SU; Purcell RH; Bukh J
Hepatology; 2000 Sep; 32(3):618-25. PubMed ID: 10960458
[TBL] [Abstract][Full Text] [Related]
8. Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study.
Chung RT; Gordon FD; Curry MP; Schiano TD; Emre S; Corey K; Markmann JF; Hertl M; Pomposelli JJ; Pomfret EA; Florman S; Schilsky M; Broering TJ; Finberg RW; Szabo G; Zamore PD; Khettry U; Babcock GJ; Ambrosino DM; Leav B; Leney M; Smith HL; Molrine DC
Am J Transplant; 2013 Apr; 13(4):1047-1054. PubMed ID: 23356386
[TBL] [Abstract][Full Text] [Related]
9. Viral persistence, antibody to E1 and E2, and hypervariable region 1 sequence stability in hepatitis C virus-inoculated chimpanzees.
Bassett SE; Thomas DL; Brasky KM; Lanford RE
J Virol; 1999 Feb; 73(2):1118-26. PubMed ID: 9882313
[TBL] [Abstract][Full Text] [Related]
10. Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients.
Eren R; Landstein D; Terkieltaub D; Nussbaum O; Zauberman A; Ben-Porath J; Gopher J; Buchnick R; Kovjazin R; Rosenthal-Galili Z; Aviel S; Ilan E; Shoshany Y; Neville L; Waisman T; Ben-Moshe O; Kischitsky A; Foung SK; Keck ZY; Pappo O; Eid A; Jurim O; Zamir G; Galun E; Dagan S
J Virol; 2006 Mar; 80(6):2654-64. PubMed ID: 16501075
[TBL] [Abstract][Full Text] [Related]
11. Native Folding of a Recombinant gpE1/gpE2 Heterodimer Vaccine Antigen from a Precursor Protein Fused with Fc IgG.
Logan M; Law J; Wong JAJ; Hockman D; Landi A; Chen C; Crawford K; Kundu J; Baldwin L; Johnson J; Dahiya A; LaChance G; Marcotrigiano J; Law M; Foung S; Tyrrell L; Houghton M
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795422
[TBL] [Abstract][Full Text] [Related]
12. Escape of Hepatitis C Virus from Epitope I Neutralization Increases Sensitivity of Other Neutralization Epitopes.
Gu J; Hardy J; Boo I; Vietheer P; McCaffrey K; Alhammad Y; Chopra A; Gaudieri S; Poumbourios P; Coulibaly F; Drummer HE
J Virol; 2018 May; 92(9):. PubMed ID: 29467319
[TBL] [Abstract][Full Text] [Related]
13. A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance.
Urbanowicz RA; McClure CP; Brown RJ; Tsoleridis T; Persson MA; Krey T; Irving WL; Ball JK; Tarr AW
J Virol; 2015 Dec; 90(7):3288-301. PubMed ID: 26699643
[TBL] [Abstract][Full Text] [Related]
14. New therapeutic options for HCV infection in the monoclonal antibody era.
Sautto GA; Diotti RA; Clementi M
New Microbiol; 2012 Oct; 35(4):387-97. PubMed ID: 23109006
[TBL] [Abstract][Full Text] [Related]
15. A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1.
Johnson J; Freedman H; Logan M; Wong JAJ; Hockman D; Chen C; He J; Beard MR; Eyre NS; Baumert TF; Tyrrell DL; Law JLM; Houghton M
J Virol; 2019 Nov; 93(22):. PubMed ID: 31462563
[TBL] [Abstract][Full Text] [Related]
16. A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells.
Rosa D; Campagnoli S; Moretto C; Guenzi E; Cousens L; Chin M; Dong C; Weiner AJ; Lau JY; Choo QL; Chien D; Pileri P; Houghton M; Abrignani S
Proc Natl Acad Sci U S A; 1996 Mar; 93(5):1759-63. PubMed ID: 8700831
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the immune response against hepatitis C infection in recovered, and chronically infected chimpanzees.
Shata MT; Anthony DD; Carlson NL; Andrus L; Brotman B; Tricoche N; McCormack P; Prince A
J Viral Hepat; 2002 Nov; 9(6):400-10. PubMed ID: 12431201
[TBL] [Abstract][Full Text] [Related]
18. Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus.
Johansson DX; Voisset C; Tarr AW; Aung M; Ball JK; Dubuisson J; Persson MA
Proc Natl Acad Sci U S A; 2007 Oct; 104(41):16269-74. PubMed ID: 17911260
[TBL] [Abstract][Full Text] [Related]
19. Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion.
Haberstroh A; Schnober EK; Zeisel MB; Carolla P; Barth H; Blum HE; Cosset FL; Koutsoudakis G; Bartenschlager R; Union A; Depla E; Owsianka A; Patel AH; Schuster C; Stoll-Keller F; Doffoël M; Dreux M; Baumert TF
Gastroenterology; 2008 Nov; 135(5):1719-1728.e1. PubMed ID: 18718838
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo.
von Hahn T; Yoon JC; Alter H; Rice CM; Rehermann B; Balfe P; McKeating JA
Gastroenterology; 2007 Feb; 132(2):667-78. PubMed ID: 17258731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
